跳至主要内容
临床试验/2024-513435-24-01
2024-513435-24-01已完成2 期

J4F-MC-CYAB: A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study Evaluating LY3848575 in Chronic Neuropathic Pain Associated With Distal Sensory Polyneuropathy

Eli Lilly & Co.13 个研究点 分布在 2 个国家目标入组 67 人开始时间: 2025年6月9日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
入组人数
67
试验地点
13
主要终点
Mean Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS)

研究概览

简要总结

To demonstrate that at least 1 dose of LY3848575 is superior to placebo in pain intensity

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • Are at least 18 years or older old at time of ICF signature.
  • Have moderate to severe pain nerve pain at least 6 months prior to screening.
  • Are willing to discontinue all medications taken for chronic pain conditions.
  • Not be able to become pregnant.

排除标准

  • Have other sources of pain that interfere with assessing nerve pain
  • Have uncontrolled diabetes.
  • Have a surgery planned.
  • Have had chemotherapy for cancer in the last year that led to nerve pain
  • Have history within 2 years of study entry of alcohol or substance use disorder

研究组 & 干预措施

Placebo to match LY3848575

Placebo

干预措施: Placebo to match LY3848575 (Drug)

结局指标

主要结局

Mean Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS)

Mean Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS)

次要结局

未报告次要终点

研究者

申办方类型
Pharmaceutical company
责任方
Principal Investigator
主要研究者

Lilly Clinical Trials information desk

Scientific

Eli Lilly & Co.

研究点 (13)

Loading locations...

相似试验